New drug combo aims to boost bile duct cancer treatment

NCT ID NCT07107750

First seen Dec 16, 2025 · Last updated May 06, 2026 · Updated 21 times

Summary

This early-phase trial tests whether adding the experimental drug emavusertib to standard chemotherapy and immunotherapy can improve outcomes for people with advanced bile duct or gallbladder cancer that has not been treated before. The study will enroll about 48 participants to first check safety and find the best dose, then see how well the combination controls the cancer. The goal is to make standard treatments work better by targeting a specific immune pathway.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.